Order results by:
| Issue | Title | |
| Vol 17, No 4 (2024) | Scenario modeling of the drug prescription process for children: application of machine learning methods | Abstract similar documents |
| А. А. Kondrashov, М. М. Kurashov, Е. Е. Loskutova | ||
| "... prescribtion for children, evaluating its performance and potential for implementation into scenario modeling ..." | ||
| Vol 16, No 4 (2023) | Comparative chemomicrobiomic analysis of bacteriocins | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova | ||
| "... and the area under the growth curve (AUC) values for a representative sample of normobiota (38 human commensal ..." | ||
| Vol 15, No 3 (2022) | Economic burden of the novel coronavirus infection: a systematic review | Abstract similar documents |
| V. M. Timiryanova, I. A. Lakman, N. Sh. Zagidullin, D. F. Gareeva | ||
| "... of constructing scenario models, 28.8% consume algorithms of epidemiological SIR (susceptible, infected ..." | ||
| Vol 14, No 4 (2021) | Economic burden of chronic viral hepatitis C | Abstract similar documents |
| R. A. Yakhina, I. A. Lakman, D. A. Valishin, R. Kh. Bakhitova | ||
| "... of assessment under study, but also to the instrumental (including mathematical) means of scenario assessment ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... modeling scenario was to increase the frequency of рroprotein convertase subtilisin/kexin type 9 (PCSK9 ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... to the healthcare system of the Russian Federation (RF). The main scenario accounted for ICD implantation cost ..." | ||
| Vol 14, No 3 (2021) | COVID-19 pandemic prediction model based on machine learning in selected regions of the Russian Federation | Abstract similar documents |
| D. V. Gavrilov, R. V. Abramov, А. V. Kirilkina, А. А. Ivshin, R. E. Novitskiy | ||
| "... регрессией на примере величины среднеквадратичной ошибки (англ. root mean square error, RMSE). Модель ..." | ||
| Vol 14, No 1 (2021) | Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy | Abstract similar documents |
| V. A. Lemeshko, K. I. Matrenin, V. V. Omelyanovskiy, Yu. V. Vasilyeva, G. R. Khachatryan, L. A. Kolganov | ||
| "... апробации методики выбраны национальные перечни России, Англии и Италии. Предложено использовать три ..." | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract similar documents |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| "... . In all simulated scenarios, in the group of patients with AF who had undergone PCI, pharmacotherapy ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... ) возбудителя с использованием метода фармакоэкономического моделирования (модель Маркова). Материал и методы ..." | ||
| Vol 17, No 2 (2024) | Mathematical modeling and analysis of export trends for certain pharmaceutical groups | Abstract similar documents |
| А. R. Shaikhislamova, N. А. Gasratova | ||
| "... фармацевтической отрасли. Цель: построить регрессионную модель экспорта и разработать альтернативную ..." | ||
| Vol 10, No 4 (2017) | PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... to therapy of hemophilia A in the RF and two additional treatment scenarios are proposed. A partial switch ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... of the Russian Federation in three scenarios: Lacosamide as concomitant drug to standard therapy in comparison ..." | ||
| Vol 17, No 4 (2024) | Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system | Abstract similar documents |
| A. V. Rudakova, I. Z. Gaydukova | ||
| "... be considered as the preferred therapeutic option in comparable clinical scenarios for active AS, thereby ..." | ||
| Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
| A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
| "... patent protection by generics or biosimilars over 5 years was simulated. Two replacement scenarios were ..." | ||
| Vol 6, No 2 (2013) | HTA CORE MODEL | Abstract similar documents |
| R. I. Yagudina, T. Yu. Nor, A. D. Sevostyanov | ||
| "... Базовая Модель ОТЗ – система стандартизированной оценки технологий здравоохранения (ОТЗ ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... analysis (BIA), two scenarios were simulated: 1. DTC treatment using sorafenib and the chemotherapeutic ..." | ||
| Vol 15, No 1 (2022) | Efficacy of targeted drugs for the treatment of adults with moderate-to-severe plaque psoriasis in the Russian Federation: a systematic literature review update | Abstract similar documents |
| V. D. Sokolova, N. A. Sableva, V. V. Mladov, D. G. Tolkacheva | ||
| "... (англ. number needed to treat, NNT) для достижения ответа на терапию, и затрат на его достижение (англ ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... профилактики развития тяжелого течения заболевания. Материал и методы. С помощью моделей древа решений и ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... фенотипом методом моделирования. Расчет затрат выполнен в математической модели, адаптированной к российским ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... . BIA compared two scenarios: 1) common practice consisting of sorafenib and Other chemotherapies mix; 2 ..." | ||
| Vol 7, No 2 (2014) | PARAMETERS OF HEALTH CARE SYSTEMS | Abstract similar documents |
| V. V. Omelyanovskiy, I. V. Maksimova, A. P. Tatarinov | ||
| "... в любой стране выбор оптимальной модели здравоохранения имеет принципиальное значение для ..." | ||
| Vol 12, No 1 (2019) | Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan | Abstract similar documents |
| T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova | ||
| "... two scenarios: the basic case when IBD patients are treated according to the current practice based ..." | ||
| Vol 16, No 1 (2023) | Prospects for using high-throughput sequencing methods to identify new biomarkers of response and resistance to antitumor therapy | Abstract similar documents |
| M. А. Sorokina, T. R. Grishina | ||
| "... Технологии высокопроизводительного секвенирования (англ. next-generation sequencing, NGS), такие ..." | ||
| Vol 7, No 3 (2014) | MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN | Abstract similar documents |
| V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan | ||
| "... of tuberculosis activation and related costs for scenarios with alternative use of T-SPOT.TB and TST ..." | ||
| Vol 7, No 4 (2014) | MODELING IN CLINICO-ECONOMIC ANALYSIS OF MEDICAL ORGANIZATIONAL TECHNOLOGIES | Abstract similar documents |
| M. A. Shapovalova, A. R. Umerova, V. A. Bondarev, L. R. Koretskaya | ||
| "... древо решений и модель Маркова мы применили для проведения расчета ожидаемых затрат при сравнении ..." | ||
| Vol 9, No 1 (2016) | MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 | Abstract similar documents |
| A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum | ||
| "... математические линейные модели. Цель. Построение модели по данным анализа перечней на 2016 г. Материалы и ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... анализ «затраты – эффективность» (англ. cost-effectiveness analysis, CEA) использования ланреотида или ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... у взрослых пациентов с распространенным положительным на киназу анапластической лимфомы (англ ..." | ||
| Vol 18, No 1 (2025) | Comparative estimation of the effectiveness of the Khorana, Vienna CATS, and TiC-Onco scores and the vWF/ADAMTS13 ratio in identifying a high risk of thrombotic complications in patients with malignant neoplasms | Abstract similar documents |
| A. V. Vorobеv, A. G. Solopova, V. O. Bitsadze, M. M. Baeva, M. E. Sosnyagova, V. N. Galkin, D. O. Utkin, A. D. Makatsariya | ||
| "... -Onco, а также измеряли уровни фактора фон Виллебранда (англ. von Willebrand factor, vWF) и фермента ..." | ||
| Vol 13, No 3 (2020) | Chemomicrobiomic analysis of glucosamine sulfate, prebiotics and non-steroidal anti-inflammatory drugs | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. V. Naumov, V. A. Maksimov | ||
| "... , fructose) as molecules of comparison. For each substance, estimates of the area under the curve (AUC) were ..." | ||
| Vol 16, No 4 (2023) | Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma | Abstract similar documents |
| S. K. Zyryanov, K. V. Orlova | ||
| "... метастатической или неоперабельной меланомой кожи. Материал и методы. Разработана комплексная модель Маркова и ..." | ||
| Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
| E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
| "... (англ. Systemic Coronary Risk Estimation), внедряемой в клиническую практику. Материал и методы. Для ..." | ||
| Vol 12, No 3 (2019) | Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019 | Abstract similar documents |
| D. V. Fedyaev , V. V. Omelyanovskiy , M. L. Lazareva , Yu. V. Seryapina, Yu. A. Ledovskikh | ||
| "... В статье рассматривается развитие модели клинико-статистических групп (КСГ) и заложенных в нее ..." | ||
| Vol 13, No 4 (2020) | Development of a method for calculation of demand for medical personnel in the healthcare of the Russian Federation, using a mathematical model | Abstract similar documents |
| V. V. Omelyanovsky, T. V. Semenova, D. V. Lukyantseva, D. V. Fedyaev, E. A. Shalaeva | ||
| "... кадрах в здравоохранении Российской Федерации с использованием математической модели балансировки ..." | ||
| Vol 17, No 2 (2024) | Study of lithium carbonate and ascorbate proliferative properties on transplantable Lewis lung carcinoma metastasis model | Abstract similar documents |
| D. E. Frolova, I. Yu. Torshin, V. V. Rastashansky, M. V. Filimonova, O. A. Gromova | ||
| Vol 17, No 4 (2024) | Study of the effect of human placenta hydrolysate in a new model of metabolic-associated fatty liver disease with iron overload | Abstract similar documents |
| T. E. Bogacheva, O. A. Gromova, I. Yu. Torshin, V. I. Demidov, A. G. Kalacheva, A. A. Garanin, I. V. Gogoleva, L. E. Fedotova, O. A. Limanova, А. N. Mnatsakanyan, N. Yu. Zhidomorov, T. R. Grishina | ||
| "... разработано специальных средств лечения, малочисленны и экспериментальные модели, на которых могли бы ..." | ||
| Vol 13, No 3 (2020) | Evaluation of the antitumor drugs therapeutic value using the method of multicriterial analysis of decision-making | Abstract similar documents |
| V. A. Lemeshko, N. Z. Musina, V. V. Omelyanovskiy | ||
| "... ≪Доказательства и ценность критериев: влияние на принятие решений≫ (англ. – Evidence and Value: Impact on ..." | ||
| Vol 16, No 3 (2023) | Clinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region | Abstract similar documents |
| A. D. Ermolaeva, T. N. Ermolaeva, K. A. Kokushkin | ||
| "... пролечить (англ. number needed to treat, NNT). Проведен анализ влияния на бюджет, в рамках которого ..." | ||
| Vol 16, No 4 (2023) | Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation | Abstract similar documents |
| M. V. Zhuravleva, K. A. Kokushkin, E. A. Luchinin, E. V. Luchinina, T. R. Kameneva, E. V. Kuznetsova, V. S. Krysanova, E. V. Makarova, L. G. Zhukova | ||
| "... железы (РМЖ), положительном на рецептор эпидермального фактора роста 2-го типа (англ. human epidermal ..." | ||
| Vol 18, No 2 (2025) | Results of adaptation of tools for standardizing value-based outcomes: analysis of ICHOM Standard Sets | Abstract similar documents |
| I. I. Khayrullin, V. V. Omelyanovskiy, R. V. Gostishchev, J. A. Agafonova, N. S. Giliazetdinova, I. A. Mikhailov | ||
| "... Актуальность. Ценностно-ориентированное здравоохранение (ЦОЗ) – это модель медицинской помощи ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... рецептора запрограммированной клеточной гибели 1 (англ. programmed death-ligand 1, PD-L1) атезолизумабом ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... . Разработана модель разделенной выживаемости. Вводные данные и их дальнейшая компьютерная обработка (оцифровка ..." | ||
| Vol 5, No 2 (2012) | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS | Abstract similar documents |
| A. V. Rudakova | ||
| Vol 15, No 2 (2022) | Experience of implementing a value-based approach in oncodermatology | Abstract similar documents |
| Yu. A. Zuenkova, D. I. Kicha, L. N. Izyurov | ||
| "... внешним видом (по психометрической модели Раша) составил 43,5 балла. Более молодые больные (r=–0,398, p=0 ..." | ||
| Vol 14, No 2 (2021) | Impact of disease information (Ebola and COVID-19) on the pharmaceutical sector in Russia and USA | Abstract similar documents |
| E. A. Fedorova, D. O. Afanasyev, A. V. Sokolov, M. P. Lazarev | ||
| "... фармацевтических компаний оценивалось с помощью эконометрической модели ARMAX–GARCH. Результаты. Было доказано ..." | ||
| Vol 16, No 2 (2023) | Development of methodological approaches to the formation of a risk-based model to minimize the prevalence of adverse reactions in drug application in medical organizations of Moscow | Abstract similar documents |
| E. V. Kuznetsova, M. V. Zhuravleva, I. A. Mikhailov, T. I. Kurnosova | ||
| "... -ориентированной модели, на которую наложена «тепловая карта» уровня риска. Максимальное суммарное значение риска ..." | ||
| Online First | Antitumor effects of vitamin B12 in vitro, in vivo, in silico | Abstract similar documents |
| O. A. Gromova, D. E. Frolova, I. Yu. Torshin, M. V. Filimonova, M. A. Sorokina, I. A. Reyer, O. A. Limanova, L. E. Fedotova, L. A. Maiorova | ||
| "... клеточной модели in vitro использовались клетки линий BT-474 (карцинома протока молочной железы) и A549 ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... Цель работы – создать модель исходов сахарного диабета 2-го типа, валидированную для применения в ..." | ||
| Vol 13, No 3 (2020) | The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups | Abstract similar documents |
| E. V. Derkach, E. A. Pyadushkina, M. V. Avxentyeva, T. V. Boyarskaya, E. E. Yagnenkova, A. S. Mokrova, M. M. Maryanyan | ||
| "... возможностей применения различных ГИБП и СИ при действующей модели оплаты по КСГ на примерах бронхиальной астмы ..." | ||
| 1 - 50 of 168 Items | 1 2 3 4 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
